Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Loerenskog – page 96

1 469 clinical trials in Loerenskog, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Loerenskog at a glance
1 469
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 469 trials in Loerenskog

Open in trial search

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:F. Hoffmann-La Roche AG

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Nivolumab and Cabozantinib with Sunitinib for Patients with Untreated Advanced Kidney Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Malignant melanoma+1

Not recruiting

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiovascular disorder+1

Not recruiting

Study on Long-Term Effects of Lerodalcibep for Lowering Cholesterol in Patients with Familial Hypercholesterolemia or Cardiovascular Disease Risks

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lerodalcibep
  • Sponsor:LIB Therapeutics Inc.

Renal cell carcinoma+1

Not recruiting

Study of Axitinib and Immune Checkpoint Inhibitors for Patients with Untreated Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study on Patidegib Gel for Reducing Basal Cell Carcinomas in Adults with Gorlin Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Patidegib Hydrochloride Isopropanolate
  • Sponsor:Sol-Gel Technologies Ltd.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alnuctamab
  • Sponsor:Celgene International II S.a.r.l.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Loerenskog

What the registry says about research in the country

01 Respiratory Conditions

Research focusing on pulmonary diseases including trials for new treatments in idiopathic pulmonary fibrosis and COPD. Studies evaluating innovative therapies for chronic wet cough in children and investigating respiratory complications in systemic autoimmune conditions.

  • Pulmonary Fibrosis Treatment
  • COPD Management
  • Pediatric Respiratory Care

Advanced clinical research examining both medication efficacy and symptom management approaches.

02 Gastrointestinal Disorders

Comprehensive studies on inflammatory bowel diseases, including trials for Ulcerative Colitis and Crohn's Disease. Research extends to liver conditions like Primary Sclerosing Cholangitis and colorectal cancer treatments.

  • IBD Treatments
  • Liver Disease Therapies
  • Colorectal Cancer Diagnostics

Innovative approaches focusing on long-term disease management and diagnostic advancement.

03 Oncology Research

Groundbreaking trials in hematological malignancies and solid tumors, including studies on chronic lymphocytic leukemia, lung cancer, and mesothelioma. Focus on combination therapies and targeted treatments.

  • Blood Cancer Treatments
  • Lung Cancer Therapy
  • Novel Cancer Medications

Advanced therapeutic approaches combining immunotherapy with conventional treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.